Exp Clin Endocrinol Diabetes 2018; 126(01): 61-65
DOI: 10.1055/s-0043-109700
Article
© Georg Thieme Verlag KG Stuttgart · New York

Risk Factors for Premature Death in Diabetes Patients who Undergo Amputations below Ankle Level

Therese E. Wilbek
3   Department of Endocrinology, University of Copenhagen, Bispebjerg Hospital, Denmark
,
Rasmus B. Jansen
3   Department of Endocrinology, University of Copenhagen, Bispebjerg Hospital, Denmark
,
Bo Jørgensen
1   Copenhagen Diabetes Foot Center, University of Copenhagen, Bispebjerg Hospital, Denmark
,
Ole Lander Svendsen
1   Copenhagen Diabetes Foot Center, University of Copenhagen, Bispebjerg Hospital, Denmark
2   Copenhagen Wound Healing Center, University of Copenhagen, Bispebjerg Hospital, Denmark
3   Department of Endocrinology, University of Copenhagen, Bispebjerg Hospital, Denmark
› Author Affiliations
Further Information

Publication History

received 12 January 2017
revised 25 April 2017

accepted 25 April 2017

Publication Date:
04 July 2017 (online)

Abstract

Aim To identify risk factors for early death in diabetes patients who undergo amputations below the ankle.

Methods A retrospective study, where all hospital records of all diabetes patients who had undergone minimum one amputation below the ankle at the CWHC Bispebjerg Hospital, Denmark, in the period 1996–2013, were examined. The amputations were mainly trans-metatarsal amputations and partial amputations of toes. The participants were found via ICD10-codes. The included patients were followed from their first contact to the last registered contact. The statistical analysis in this article is performed on patients with a of minimum 5-year follow-up.

Results The 5 year mortality was 42% for patients with type 2 diabetes, and 29% for patients with type 1 diabetes. For patients with type 2 diabetes, multivariable analysis showed that high age, peripheral arterial insufficiency and short time from first admission to amputation were independently statistically significantly associated with increased 5-years mortality. Use of statins was associated with decreased mortality. 35% died as a result of their diabetes, mostly due to cardiovascular causes.

Conclusion Short time from first admission to amputation is a risk factor for early death. Arterial insufficiency and high age is also associated with increased mortality, whereas use of statin is associated with decreased mortality, in patients with type 2 diabetes.

 
  • References

  • 1 WHO. Diabetes Fact Sheets. Diabetes 2015 January 2015 [cited 2016 10-02-2016]
  • 2 Papazafiropoulou A, Tentolouris N, Soldatos RP. et al. Mortality in diabetic and nondiabetic patients after amputations performed from 1996 to 2005 in a tertiary hospital population: a 3-year follow-up study. J Diabetes Complications 2009; 23: 7-11
  • 3 Wilbek TE, Jansen RB, Jorgensen B. et al. The diabetic foot in a – Multidisciplinary team setting. Number of amputations below ankle level and mortality. Exp Clin Endocrinol Diabetes 2016; 124: 535-540
  • 4 Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003; 26: 491-494
  • 5 Uzzaman MM, Jukaku S, Kambal A. et al. Assessing the long-term outcomes of minor lower limb amputations: a 5-year study. Angiology 2011; 62: 365-371
  • 6 Icks A, Scheer M, Morbach S. et al. Time-dependent impact of diabetes on mortality in patients after major lower extremity amputation: Survival in a population-based 5-year cohort in Germany. Diabetes Care 2011; 34: 1350-1354
  • 7 Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996; 13 (Suppl. 01) S6-S11
  • 8 Armstrong DG, Lavery LA, Quebedeaux TL. et al. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetic versus nondiabetic adults. South Med J 1997; 90: 384-389
  • 9 Coppini DV, Bowtell PA, Weng C. et al. Showing neuropathy is related to increased mortality in diabetic patients – a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-523
  • 10 Kelly PJ, Clarke PM, Hayes AJ. et al. Predicting mortality in people with type 2 diabetes mellitus after major complications: A study using Swedish National Diabetes Register data. Diabet Med 2014; 31: 954-962
  • 11 Tentolouris N, Al-Sabbagh S, Walker MG. et al. Mortality in diabetic and nondiabetic patients after amputations performed From 1990 to 1995. Diabetes Care 2004; 27: 7
  • 12 Campbell WB, Ponette D, Sugiono M. Long-term results following operation for diabetic foot problems: Arterial disease confers a poor prognosis. Eur J Vasc Endovasc Surg 2000; 19: 174-177
  • 13 Rubio JA, Aragon-Sanchez J, Jimenez S. et al. Reducing major lower extremity amputations after the introduction of a multidisciplinary team for the diabetic foot. Int J Low Extrem Wounds 2014; 13: 22-26
  • 14 IBM. IBM SPSS Statistics
  • 15 Tatoulis J, Wynne R, Skillington PD. et al. Total Arterial Revascularization: A superior strategy for diabetic patients who require coronary surgery. Ann Thorac Surg 2016; 102: 1948-1955
  • 16 Inan B, Aydin U, Ugurlucan M. et al. Surgical treatment of lower limb ischemia in diabetic patients – long-term results. Arch Med Sci 2013; 9: 1078-1082
  • 17 Ballotta E, Toniato A, Piatto G. et al. Lower extremity arterial reconstruction for critical limb ischemia in diabetes. J Vasc Surg 2014; 59: 708-719
  • 18 Sohn MW, Meadows JL, Oh EH. et al. Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg 2013; 58: 1578-1585
  • 19 Hero C, Rawshani A, Svensson AM. et al. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care. 2016; 39: 996-1003
  • 20 Cholesterol Treatment Trialist’ (CTT) Collaborators. Kearny PM, Blackwell L, Collins R. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371: 117-125
  • 21 Shepherd J, Barter P, Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226